eplontersen sodium · Astrazeneca Ab · NDA 217388
Wainua
Earliest generic entry, as listed
25 Aug 2034
Blocked by patent: US 10683499.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10683499 | substance, product, use U-2378 | 25 Aug 2034 |
| US 9127276 | substance | 1 May 2034 |
| US 9181549 | substance | 1 May 2034 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217388 · 002 · RLD | solution, subcutaneous | EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML) | 25 Aug 2034 |